ArticleJournal of medicinal chemistry2026
Probing Immune Signatures of Conjugated Pattern Recognition Receptor Ligands Identifies Chimeras with Potent Adjuvant and Antitumor Activities.
Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Conjugated NOD1-Centered Dual Agonists Exhibit Modest In Vitro Immunomodulation but Potent In Vivo Adjuvanticity.ACS bio & med chem Au · 2026Article
- Review
- Modulating Receptor Activity, Immune Response, and Kinetic Solubility: The Impact of Linker Chemistry in Conjugated NOD2/TLR4 Agonists.ACS omega · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pattern recognition receptor (PRR) ligands represent a promising class of immunostimulants. Here, we demonstrate that the covalent conjugation of PRR ligands enables coordinated receptor engagement and amplifies immune responses beyond those achievable with unlinked mixtures. We synthesized a focused panel of chimeric PRR ligands comprising defined pairwise agonist combinations targeting selected extracellular and intracellular PRRs. Using phenotypic screening in human peripheral blood mononuclear cells, we identified conjugates that induced distinct cytokine signatures and enhanced cytotoxic immune activity. Among these, chimeric TLR4/TLR7 and TLR7/RIG-I ligands elicited broad innate immune activation in vitro and enhanced antigen-specific immune responses in murine vaccination models. Notably, intratumoral administration of the conjugated TLR4/TLR7 ligand resulted in significant antitumor activity in a syngeneic B16F10 melanoma model. Collectively, these findings establish covalent PRR ligand conjugation as a powerful chemical strategy for modulating innate immune signaling and support the development of conjugated PRR ligands as next-generation vaccine adjuvants and immunotherapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.